Tenderwize
Back to tender search

Open House Biologic Discount Agreements 2025-18 - Insulin glargin (100 U/ml)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 377 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-18 - Insulin glargin (Wirkstärke: 100 U/ml)

40/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

60 / 100

Risk factors

The procedure is not a public procurement subject to procurement review; disputes go to social courts. Legal recourse i...

No estimated value – potential revenue is unknown. Contract may attract many participants, diluting volume.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Execution of a discount agreement (Rabattvertrag) for Insulin glargin (100 U/ml) with participating health insurance funds.
  • Supply of the pharmaceutical product under standardized conditions for up to 24 months.
Show full summary

This is an Open-House procedure for pharmaceutical discount agreements (Rabattverträge) on Insulin glargin (100 U/ml) with multiple German statutory health insurance funds led by Techniker Krankenkasse. The procedure is open to all qualified pharmaceutical entrepreneurs who meet the eligibility criteria. The contract term is up to 24 months starting from 1 September 2025 (with a later start for hkk on 1 October 2025) and ending no later than 31 August 2027. No estimated value is provided. The award is based solely on meeting eligibility requirements, not on competition. Electronic submission is not allowed via the portal; contracts must be submitted by email (with qualified electronic signature) or by post.

Risks

The procedure is not a public procurement subject to procurement review; disputes go to social courts. Legal recourse i...

No estimated value – potential revenue is unknown. Contract may attract many participants, diluting volume.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product in Germany or be entitled to place it on the market under own name.
  • Seat must be in Germany, another EU member state, or an EEA state.

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Biologic Discount Agreements 2025-18 - Insulin glargin (100 U/ml)

Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Insulin glargin (Wirkstärke: 100 U/ml) im Rahmen eines Open-House-Verfahrens. The lot covers nationwide supply of Insulin glargin with a maximum contract duration of 24 months.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Aug 2025 - Aug 2027

Category

Pharmaceutical products

Deadline

Deadline Aug 30, 2027

Procurement Details

Publication date
09 Jun 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
372143-2025

Documents (1)

Similar tenders